Silence Therapeutics

72 Hammersmith Road
London,  W14 8TH

United Kingdom
https://www.silence-therapeutics.com/
  • Booth: 3241

Silence Therapeutics is a biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA technology.  SLN124 is our wholly owned siRNA in clinical development to potentially address a range of hematological conditions through its ability to modulate hepcidin, the body's master iron regulator. SLN124 is being evaluated in a phase 1 study in thalassemia and a phase 1/2 study in polycythemia vera. For more information, please visit https://www.silence-therapeutics.com/.

Silence Therapeutics is developing a pipeline of siRNA (short interfering RNA) therapeutics using its proprietary mRNA GOLD™ platform. Silence’s pipeline includes wholly owned and partnered programs aimed to address genetic diseases with high unmet need. SLN124 is Silence’s wholly owned product candidate in clinical development for beta thalassemia and polycythemia vera. SLN124 works by silencing the TMPRSS6 gene and has demonstrated pre-clinical potential in a range of hematological diseases.